The DETECTION study (NCT04901988) was a randomized phase II/III study to compare recurrence surveillance in stage IIB/C melanoma with BRAF, NRAS, or TERT promoter mutations between the standard group (in which follow-up observation was performed until recurrence without regard for MRD test results) and the MRD-guided group (in which MRD-positive patients received nivolumab) [96]. The gene discussed is BRAF; the disease is melanoma.